Sintx Technologies (SINT) FY2025 10-K Risk Factors: 11 New, 6 Dropped

What the changes say

Sintx Technologies highlights its commercial transition following the spine business sale, now relying on distributors and its new direct sales force for products like the SiNAPTIC foot and ankle wedge system, while facing ongoing net losses, capital needs, and regulatory and reimbursement hurdles.

What changed since the prior 10-K

New

NewRisks Related to Our Business and Strategy
Our biomedical products may not achieve market acceptance or commercial success
We rely on third-party partners to commercialize our silicon nitride spinal fusion products and have not achieved significant market share.
NewRisks Related to Our Business and Strategy
Our newer offerings, including the SiNAPTIC® foot and ankle wedge system, and any future products for which we obtain regulatory clearance or approval, may likewise fail to gain sufficient clinical adoption
Our newer offerings, such as the SiNAPTIC foot and ankle wedge system, may fail to gain clinical adoption due to competition, pricing, or lack of data.
NewRisks Related to Our Business and Strategy
We rely on both strategic partners and our own commercialization capabilities to develop and market our product candidates, and if these efforts are unsuccessful, we may not achieve profitability
We depend on a mix of third-party partners and our own infrastructure to commercialize biomedical products and achieve profitability.
NewRisks Related to Our Business and Strategy
Building and managing an in-house sales and distribution organization subjects us to significant operational, financial, and execution risks
Building an in-house sales and distribution organization for products like the SiNAPTIC foot and ankle wedge system exposes us to high operational and recruitment risks.
NewRisks Related to Our Business and Strategy
Internationally, reimbursement systems and pricing controls vary by country, and many jurisdictions impose price ceilings or other restrictions on medical devices. Failure to obtain favorable reimbursement or pricing approvals in international markets could limit adoption of our products outside the United States
International price ceilings and reimbursement controls could limit adoption of our medical devices outside the United States.
NewRisks Related to Our Business and Strategy
Cybersecurity risks and failures of our information technology systems could disrupt our operations, compromise confidential information, and materially adversely affect our business
Cybersecurity threats to our IT systems or those of our third-party service providers could disrupt manufacturing and compromise sensitive data.
NewRisks Related to Regulatory Approval of Our Products and Other Government Regulations
Our long-term success depends on our ability to obtain and maintain regulatory clearances and approvals for our medical products and product candidates, and we may be unable to do so in a timely manner or at all
Obtaining FDA clearances through 510(k), De Novo, or PMA pathways for products like spinal implants and the SiNAPTIC system is costly and uncertain.
NewRisks Related to Regulatory Approval of Our Products and Other Government Regulations
We may be required to generate clinical or additional supporting data for certain product candidates, which could increase costs and delay commercialization
The FDA may require costly clinical trials or investigational device exemptions for future product candidates, delaying commercialization.
NewRisks Related to Regulatory Approval of Our Products and Other Government Regulations
Our relationships with healthcare providers, distributors, and third-party payers are subject to complex healthcare fraud and abuse, transparency, and privacy laws, and noncompliance could result in significant penalties and reputational harm
Noncompliance with healthcare fraud and abuse laws, such as the Anti-Kickback Statute and HIPAA, could result in penalties and reputational harm.
NewRisks Related to Regulatory Approval of Our Products and Other Government Regulations
Changes in tax laws or their interpretation could adversely affect our business and the value of our securities
Tax law changes, including the Inflation Reduction Act minimum tax and stock repurchase excise tax, could adversely affect our financial condition.
NewRisks Related to Regulatory Approval of Our Products and Other Government Regulations
Changes in healthcare laws, regulations, and reimbursement policies may increase our costs, delay regulatory review, and adversely affect pricing and demand for our products
Changes in healthcare regulations, reimbursement policies, and FDA quality management requirements could increase our compliance costs and delay product reviews.

Dropped

DroppedRisks Related to Our Business and Strategy
Our current biomedical products and our future products may not be accepted by hospitals and surgeons and may not become commercially successful
DroppedRisks Related to Our Business and Strategy
We will depend on one or more strategic partners to develop and commercialize our biomedical and antipathogenic product candidates, and if our strategic partners are unable to execute effectively on our agreements with them, we may never become profitable
DroppedRisks Related to Our Business and Strategy
Cyber security risks and the failure to maintain the integrity of company, employee or guest data could expose us to data loss, litigation and liability, and our reputation could be significantly harmed
DroppedRisks Related to Regulatory Approval of Our Products and Other Government Regulations
Our long-term success depends substantially on our ability to obtain regulatory clearance or approval and thereafter commercialize our product candidates; we cannot be certain that we will be able to do so in a timely manner or at all
DroppedRisks Related to Regulatory Approval of Our Products and Other Government Regulations
We may be required to conduct clinical trials to support regulatory approval of some of our product candidates. We have little experience conducting clinical trials, they may proceed more slowly than anticipated, and we cannot be certain that our product candidates will be shown to be safe and effective for human use
DroppedRisks Related to Regulatory Approval of Our Products and Other Government Regulations
Recently enacted and future legislation may increase the difficulty and cost for us to obtain and monitor regulatory approval or clearance of our product candidates and affect the prices we may obtain for our products
Dependence on CTL to sell manufactured spinal fusion products.

Reworded

100% rewrittenRisks Related to Our Business and Strategy
A pandemic, epidemic or outbreak of an infectious disease in the United States or elsewhere may adversely affect our business, operations, and financial condition
Updated to describe general public health emergencies and supply chain disruptions rather than focusing specifically on COVID-19.
Was: A pandemic, epidemic or outbreak of an infectious disease in the United States or elsewhere may adversely affect our business
99% rewrittenRisks Related to Our Business and Strategy
If hospitals and other healthcare providers are unable to obtain coverage or adequate reimbursement for procedures performed using our medical products, our products may not achieve widespread adoption
Expanded to include coverage and reimbursement dependencies for the SiNAPTIC foot and ankle wedge system alongside silicon nitride spinal implants.
Was: If hospitals and other healthcare providers are unable to obtain coverage or adequate reimbursement for procedures performed with our products, it is unlikely our products will be widely used
98% rewrittenRisks Related to Regulatory Approval of Our Products and Other Government Regulations
The safety and effectiveness of our products are not supported by long-term clinical data, and they may prove to be less safe or effective than our preclinical testing or limited clinical experience indicate
Clarified that 510(k) cleared products rely primarily on bench and biocompatibility testing rather than extensive long-term clinical trial data.
Was: The safety of our products is not yet supported by long-term clinical data, and they may prove to be less safe and effective than our laboratory data indicate
98% rewrittenRisks Related to Our Business and Strategy
In order to be successful, we must expand our available product lines by commercializing new product candidates, but we may not be able to do so in a timely fashion and at expected costs, or at all
Updated growth strategy to include expanding product portfolios into orthopedic and extremity markets using the SiNAPTIC foot and ankle wedge system.
65% rewrittenRisks Related to Regulatory Approval of Our Products and Other Government Regulations
Changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax returns could adversely affect our results of operations and financial condition
Retained prior year tax rate volatility factors with minor formatting adjustments.
51% rewrittenRisks Related to Our Capital Resources and Impairments
Raising additional capital by issuing securities or through debt financings or licensing arrangements will likely cause dilution to existing stockholders, restrict our operations or require us to relinquish proprietary rights
Added specific references to potential conversion and dividend rights senior to common stock when raising capital.
48% rewrittenRisks Related to Our Business and Strategy
We have incurred net losses since our inception and anticipate that we will continue to incur net losses for the foreseeable future. We may never achieve or sustain profitability
Updated financial figures for fiscal year 2025, showing a net loss of $10.4 million and an accumulated deficit of $292.1 million.
Was: We have incurred net losses since our inception and anticipate that we will continue to incur substantial net losses for the foreseeable future. We may never achieve or sustain profitability
41% rewrittenRisks Related to Our Capital Resources and Impairments
We will require additional financing and our failure to obtain additional funding would force us to delay, reduce or eliminate our product development programs or commercialization efforts
Updated liquidity figures to $4.1 million in cash as of December 31, 2025, and disclosed a $6.4 million ATM offering agreement.
40% rewrittenRisks Related to Our Business and Strategy
Our success depends on our ability to successfully commercialize advanced ceramic products for biomedical, and antipathogenic applications, which to date have experienced only limited market acceptance
33% rewrittenRisks Related to Our Business and Strategy
The orthopedic market is highly competitive, and we may not be able to compete effectively against the larger, well-established companies that dominate this market or emerging and small innovative companies that may seek to obtain or increase their share of the market
24% rewrittenRisks Related to Our Business and Strategy
We are dependent on our senior management team, engineering team, and external advisors, and the loss of any of them could harm our business. We may not have sufficient personnel to effectuate our business strategy due to our recent reduction in force

All 39 risk factors

Headings as the filing states them, in filing order.

Risks Related to Our Capital Resources and Impairments

01We will require additional financing and our failure to obtain additional funding would force us to delay, reduce or eliminate our product development programs or commercialization efforts41% rewritten
02A change in the outcome of any of these variables with respect to the development of our product candidates could mean a significant change in the costs and timing associated with the development of these product candidates
03Raising additional capital by issuing securities or through debt financings or licensing arrangements will likely cause dilution to existing stockholders, restrict our operations or require us to relinquish proprietary rights51% rewritten

Risks Related to Our Business and Strategy

04We have incurred net losses since our inception and anticipate that we will continue to incur net losses for the foreseeable future. We may never achieve or sustain profitability48% rewritten
05Our success depends on our ability to successfully commercialize advanced ceramic products for biomedical, and antipathogenic applications, which to date have experienced only limited market acceptance40% rewritten
06Our biomedical products may not achieve market acceptance or commercial successNew
07Our newer offerings, including the SiNAPTIC® foot and ankle wedge system, and any future products for which we obtain regulatory clearance or approval, may likewise fail to gain sufficient clinical adoptionNew
08The orthopedic market is highly competitive, and we may not be able to compete effectively against the larger, well-established companies that dominate this market or emerging and small innovative companies that may seek to obtain or increase their share of the market33% rewritten
09We depend on a limited number of third-party suppliers for key raw materials used in the manufacturing of our silicon nitride products, and the loss of these third-party suppliers or their inability to supply us with adequate raw materials could harm our business
10In order to be successful, we must expand our available product lines by commercializing new product candidates, but we may not be able to do so in a timely fashion and at expected costs, or at all98% rewritten
11We rely on both strategic partners and our own commercialization capabilities to develop and market our product candidates, and if these efforts are unsuccessful, we may not achieve profitabilityNew
12Building and managing an in-house sales and distribution organization subjects us to significant operational, financial, and execution risksNew
13Part of our strategy is to establish and develop OEM partnerships and arrangements, which subjects us to various risks
14If hospitals and other healthcare providers are unable to obtain coverage or adequate reimbursement for procedures performed using our medical products, our products may not achieve widespread adoption99% rewritten
15Internationally, reimbursement systems and pricing controls vary by country, and many jurisdictions impose price ceilings or other restrictions on medical devices. Failure to obtain favorable reimbursement or pricing approvals in international markets could limit adoption of our products outside the United StatesNew
16A pandemic, epidemic or outbreak of an infectious disease in the United States or elsewhere may adversely affect our business, operations, and financial condition100% rewritten
17Prolonged negative economic conditions in domestic and international markets may adversely affect us, our suppliers, partners and consumers, and could harm our financial position
18We are dependent on our senior management team, engineering team, and external advisors, and the loss of any of them could harm our business. We may not have sufficient personnel to effectuate our business strategy due to our recent reduction in force24% rewritten
19If we experience significant disruptions in our information technology systems, our business, results of operations and financial condition could be adversely affected
20Cybersecurity risks and failures of our information technology systems could disrupt our operations, compromise confidential information, and materially adversely affect our businessNew

Risks Related to Regulatory Approval of Our Products and Other Government Regulations

21Contracting with government entities exposes us to additional risks inherent in the government procurement process
22We design, manufacture and service products that incorporate advanced technologies; the introduction of new products and technologies involves risks, and we may not realize the degree or timing of benefits initially anticipated; competition may reduce our revenues and segment share and limit our future opportunities
23Exports and imports of certain of our products are subject to various export control, sanctions and import regulations and may require authorization from regulatory agencies of the U.S. or other countries
24Our long-term success depends on our ability to obtain and maintain regulatory clearances and approvals for our medical products and product candidates, and we may be unable to do so in a timely manner or at allNew
25The safety and effectiveness of our products are not supported by long-term clinical data, and they may prove to be less safe or effective than our preclinical testing or limited clinical experience indicate98% rewritten
26We may be required to generate clinical or additional supporting data for certain product candidates, which could increase costs and delay commercializationNew
27Our relationships with healthcare providers, distributors, and third-party payers are subject to complex healthcare fraud and abuse, transparency, and privacy laws, and noncompliance could result in significant penalties and reputational harmNew
28Changes in effective tax rates or adverse outcomes resulting from examination of our income or other tax returns could adversely affect our results of operations and financial condition65% rewritten
29Changes in tax laws or their interpretation could adversely affect our business and the value of our securitiesNew
30Changes in healthcare laws, regulations, and reimbursement policies may increase our costs, delay regulatory review, and adversely affect pricing and demand for our productsNew

Risks Related to Our Intellectual Property and Litigation

31If the combination of patents, trade secrets and contractual provisions that we rely on to protect our intellectual property is inadequate, our ability to commercialize our products successfully will be harmed, and we may not be able to operate our business profitably
32We have no patent protection covering the composition of matter for our solid silicon nitride or for all of the components of the process we use for manufacturing our silicon nitride, and competitors may create silicon nitride formulations substantially similar to ours
33We may be subject to damages resulting from claims that we have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition agreements with our competitors or non-solicitation agreements
34If our advanced ceramic products or our product candidates conflict with the rights of others, we may not be able to manufacture or market our products or product candidates, which could have a material and adverse effect on us

Risks Related to Potential Litigation from Operating Our Business

35We may become subject to potential product liability claims, and we may be required to pay damages that exceed our insurance coverage
36Any claims relating to our improper handling, storage or disposal of biological or hazardous materials could be time consuming and costly

Risks Related to Public Companies

37We are a “smaller reporting company” and the reduced disclosure requirements applicable to smaller reporting companies may make our common stock less attractive to investors
38We incur substantial costs as a result of being a public company and our management expects to devote substantial time to public company compliance programs
39We may not be able to maintain our listing on the Nasdaq Capital Market, which would adversely affect the price and liquidity of our common stock

Other Sintx Technologies 10-Ks

FY2024 10-K risk factors
34 risks
Sintx Technologies faces severe liquidity constraints, relying heavily on third-party distributor CTL to sell its silicon nitride medical products.
Filed Mar 19, 2025

About this page

The headings are the filing's own. The one-line readings and the overview are automated and can be wrong: read Item 1A of the 10-K for the exact wording.